Tags » Chronic Lymphocytic Leukemia

FAT1 Mutations Influence Time to First Treatment in Untreated CLL

By John Allan, M.D.

Despite recent strides in mapping the mutational landscape of chronic lymphocytic leukemia (CLL) there is still limited information regarding the clinical impact of some less common gene mutations in the treatment of CLL. 272 more words

Patient Education

NICE takes Imbruvica off the CDF, available routinely against chronic lymphocytic leukaemia

Hundreds of people could benefit as NICE decision means ibrutinib can come off the Cancer Drugs Fund (CDF) and be routinely available to treat chronic lymphocytic leukaemia. 197 more words

News

Six Weeks on Ibrutinib = Minor Side Effects

So in general, I feel fine. I don’t notice that I feel any better than I did before I started Ibrutinib. Nor do I notice that I feel any worse. 400 more words

CLL

Ibrutinib

I started Ibrutinib (standard dose: three 140 mg capsules once a day) on Wednesday, and after only 3 doses, my lymph nodes have shrunk pretty dramatically. 201 more words

The US has given fast-track approval to a surprising new cancer drug

“Even when it’s killing cells, you feel great.”

A new cancer drug called Venetoclax is causing quite a stir in the medical community, with the announcement… 817 more words

ONCOLOGY

Venclexta (Venetoclax) granted U.S. FDA approval for the treatment of patients with Chronic Lymphocytic Leukemia (CLL)

Venclexta (Venetoclax) is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is over-expressed in many patients with… 304 more words

Vincent Banial